Adcock Ingram to acquire Genop Holdings

The CEO of Adcock Ingram, Andy HallIn line with its declared strategy to pursue value-adding acquisitions, particularly in less-regulated areas, Adcock Ingram has concluded a share purchase agreement to acquire 100 percent of the shares of Genop Holdings (Genop) and its subsidiaries.

Genop is a highly specialised instrument, surgical and pharmaceutical products company focussed on the ophthalmic, optometry, skin care, aesthetic and plastic surgery segments in southern Africa. The company owns and markets the Epi-max skin care range, which has high awareness amongst consumers and health care professionals alike, as well as having a strong presence in the broader dermatological area. Genop has also been one of the market leaders in the optical instruments and ophthalmic field for over 90 years.

Focus on diversification

‘We consider the Genop acquisition to present an attractive investment opportunity for Adcock Ingram, as the range is complementary to our existing portfolio with very little overlap,’ says Andy Hall, CEO of Adcock Ingram. ‘This acquisition also offers diversification into a less regulated area of the health care market with many products in the portfolio falling outside the regulated single exit price environment.’

The acquisition is subject to regulatory approvals and other conditions typical for a transaction of this nature. 

Subscribe to our mailing list

* indicates required

Would you like to receive our FREE e-newsletter?

* indicates required